{"nctId":"NCT00449956","briefTitle":"MK0507A Clinical Study in Patients With Glaucoma and Ocular Hypertension (0507A-149)(COMPLETED)","startDateStruct":{"date":"2007-03-12","type":"ACTUAL"},"conditions":["Glaucoma"],"count":474,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: dorzolamide hydrochloride (+) timolol maleate"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Comparator: timolol maleate","Drug: Comparator: dorzolamide hydrochloride"]},{"label":"3","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Comparator: timolol maleate"]}],"interventions":[{"name":"dorzolamide hydrochloride (+) timolol maleate","otherNames":[]},{"name":"Comparator: timolol maleate","otherNames":[]},{"name":"Comparator: dorzolamide hydrochloride","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with glaucoma and ocular hypertension\n\nExclusion Criteria:\n\n* History of ocular surgery within 3 months\n* Administration contradiction to timolol and dorzolamide","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Intraocular Pressure (IOP) From Baseline at 8 Weeks","description":"Change from baseline to 8 weeks in Intraocular Pressure (IOP) assessed 2 hours after ocular instillation (at Hour 2)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.50","spread":null},{"groupId":"OG001","value":"-1.82","spread":null},{"groupId":"OG002","value":"-2.78","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Intraocular Pressure (IOP) at 8 Weeks","description":"Percent Change from baseline to 8 weeks in Intraocular Pressure (IOP) assessed 2 hours after ocular instillation (at Hour 2)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.99","spread":null},{"groupId":"OG001","value":"-8.74","spread":null},{"groupId":"OG002","value":"-13.46","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Outflow Pressure Reduction Rate at 8 Weeks","description":"Percent Change from baseline to 8 weeks in Outflow Pressure Reduction Rate assessed 2 hours after ocular instillation (at Hour 2)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.47","spread":null},{"groupId":"OG001","value":"17.17","spread":null},{"groupId":"OG002","value":"26.75","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2},"commonTop":["Instillation site irritation","Nasopharyngitis","Glucose urine present","Alanine aminotransferase increased","Corneal epithelium defect"]}}}